Learn about our latest activities
NOVAST Events
Publication
Announcement
Tri-Lo-Linyah (Norgestimate and Ethinyl Estradiol Tablets) are Approved by US FDA
Tri-Lo-Linyah (Norgestimate and Ethinyl Estradiol Tablets, 0.18mg/0.025mg，0.215mg/0.025mg，0.25mg/0.025mg) are Approved b....
2022-09-03
Pramipexole Dihydrochloride ER Tablets are Approved by US FDA
NOVAST-developed Pramipexole Dihydrochloride ER Tablets received approval from US FDA and were launched into the US mark....
2022-02-09
Metoprolol Succinate ER Tablets are Approved by China NMPA
On November 5, 2021, as announced by China NMPA, NOVAST receives approval for Metoprolol Succinate ER Tablets. Name of p....
2021-11-05
NOVAST Passes On-site GMP Inspection by Jiangsu Medical Products Administration
On October 18, 2021, Jiangsu Medical Products Administration (JSMPA) released the announcement (No. 2021-81):In accordan....
2021-10-18
The First NOVAST Approval by China NMPA- Metformin Hydrochloride Sustained-release Tablets (III)
On October 9, 2021, NOVAST received our FIRST Approval notice from China NMPA. In accordance with the relevant provision....
2021-10-10
Best Supplier of the Year 2021 awarded by?Healthcare UC?(Mckesson)
NOVAST is again awarded “Best Supplier of the Year 2021” for excellence in quality, regulatory and supply ch....
2021-05-07
The 40th Novast Product is Approved by the US FDA
A NOVAST-developed non-cyclic oral contraceptive medication DOLISHALE™, the 40th product developed by NOVAST, rece....
2020-10-23
Seven More Products are Approved by US FDA
Two oral contraceptive products, two immediate-release products and three extended-release products, all NOVAST-develope....
2019-12-25
Tel:+86(513)-8598 8888
Copyright 2022 by NOVAST
